Patents Assigned to Bristol-Myers
  • Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
    Patent number: 7084162
    Abstract: Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: August 1, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter T. Cheng, Pratik Devasthale, Yoon Jeon, Sean Chen, Hao Zhang
  • Heterocyclic inhibitors of kinases
    Patent number: 7084160
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: August 1, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 7081455
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Tyrosine kinase inhibitors
    Patent number: 7081454
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Spiro-hydantoin compounds useful as anti-inflammatory agents
    Patent number: 7078420
    Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R2, R4a, R4b, and R4c are as defined in the specification.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: July 18, 2006
    Assignees: Bristol-Myers Squibb Company, Cerep SA
    Inventors: T. G. Murali Dhar, Dominique Potin, Magali Jeannine Blandine Maillet, Michele Launay, Eric Antoine Nicolai, Edwin J. Iwanowicz
  • Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
    Patent number: 7074921
    Abstract: Methods for the synthesis of benzodiazepine compounds having farnesyl protein transferase inhibitory activity.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: July 11, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: David R. Kronenthal, Rao S. Bhandaru, Zhongping Shi, Boguslaw M. Mudryk
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7074810
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: July 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Methods for blocking binding of CD28 receptor to B7
    Patent number: 7070776
    Abstract: The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. The invention further provides methods for using antibodies to B7, or fragments thereof, to regulate CD28 positive T cell response and immune responses mediated by T cells.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady
  • Production of gaseous chloramine
    Patent number: 7070751
    Abstract: The present invention provides a reactor for the gas-phase reaction of commercially available gases in the presence of an inert carrier gas to form product gas. The reactor has a streamlined, compact configuration and at least one solids collection and removal system downstream of the reactor, where solids are efficiently removed from the product gas stream, leaving high purity product gas. The removal system allows for a simple reactor design, which is easy to clean and operates continuously over longer periods of time.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Srinivas Tummala, Shun Wang Leung, Ehrlic T. Lo, Mario Moisés Alvarez
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 7071186
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Pharma Co.
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael G. Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7071333
    Abstract: The present invention provides for triazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, and R5 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald Combs, Charles M. Langevine, Yuping Qiu, Fred Christopher Zusi
  • Enzyme inhibiting adhesives
    Publication number: 20060141016
    Abstract: An adhesive composition including an adhesive component and an enzyme inhibiting component for use in ostomy and wound care applications. The enzyme inhibitors are derived from tubers, such as potatoes. In ostomy, the adhesive composition helps to secure the collection bag or pouch to the skin. In wound care application, the adhesive composition secures the wound dressing to the skin. The adhesive composition also may be used to couple two or more ostomy or wound care components together.
    Type: Application
    Filed: November 29, 2005
    Publication date: June 29, 2006
    Applicant: Bristol-Myers Squibb Company
    Inventor: Mahesh Sambasivam
  • Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same
    Patent number: 7067525
    Abstract: Compounds having the formula (I), G is a novel side chain selected from C2-6alkenyl, A3-aryl, —OR18, heteroaryl, A1-cyano, A2—OR17, A1—C(?O)R18, A1—CO2R18, A1—C(?O)NR18R19, A1—OC(?O)R18, A1—NR18C(?O)R19, A1—OC(?O)NR18R19, A1—NR18CO2R19, A1—NR18SO2R17, A1—SO2R17, A1—NR20C(?O)NR18R19, and A1—SR18; or when y is 0 or when W is not NHR22, G may be A1-heterocyclo, wherein A1 is a bond, C1-6alkylene or C2-alkenylene, A2 is C1-6alkylene or C2-6alkenylene, and A3 is C2-6alkenylene; W is selected from —NR21R22, —OR23, —NR21C(?O)R24, —NR21CO2R24, amidino, guanidino, or a heteroaryl, heterocyclo or C3-7cycloalkyl as defined in the specification, and X and R1 through R24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: June 27, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Guixue Yu, John Macor, Timothy Herpin, R. Michael Lawrence, George C. Morton, Rejean Ruel, Graham S. Poindexter, Edward H. Ruediger, Carl Thibault
  • Pyridino and pyrimidino pyrazinones
    Patent number: 7067658
    Abstract: The present invention provides compounds of Formula I: wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 27, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thais Motria Sielecki-Dzurdz, Argyrios George Arvanitis, Carolyn Diane Dzierba
  • Compression device for the limb
    Publication number: 20060135894
    Abstract: A compression device for the limb comprising a sleeve adapted to surround the limb, the sleeve comprising an inelastic layer and a cell constructed from an inner part joined to an outer part by one or more side walls so that the cell has a box-like configuration, the inner part being adapted to conform to the shape of the limb when the cell is inflated to provide an even pressure to the limb.
    Type: Application
    Filed: October 20, 2005
    Publication date: June 22, 2006
    Applicant: Bristol-Myers Squibb Company
    Inventors: Patrick G. Linnane, Ian S. Tabron, Arsenio Fernandez, Anders L. Bostrom, Peter L. Hansen, Muhammad Salim Mirza
  • Di-substituted pyrrolotriazine compounds
    Patent number: 7064203
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: June 20, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Wen-Ching Han, Ping Chen, Edward H. Ruediger, Harold Mastalerz, Brian E. Fink, Derek J. Norris
  • Enzymatic resolution of t-butyl taxane derivatives
    Patent number: 7063977
    Abstract: A method for the resolution of a mixture of the cis or trans enantiomers of a compound of the formula wherein R1 is —O—C(O)alkyl, —O—C(O)aryl or —O—C(O)cycloalkyl by contacting the mixture with a carboxylic ester hydrolase enzyme which catalyzes the stereoselective hydrolysis of the mixture and the use of such enantiomers to produce antitumor compounds which are especially suitable for oral administration.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: June 20, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Ramesh N. Patel
  • Matrix metalloproteinase inhibitors
    Patent number: 7060248
    Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: June 13, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Alan P. Carpenter, Jr., Milind Rajopadhye
  • Inhibitors of IMPDH enzyme
    Patent number: 7060720
    Abstract: The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5?-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: June 13, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Henry H. Gu, T. G. Murali Dhar, Edwin J. Iwanowicz
  • Wound dressing
    Patent number: D524946
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: July 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Helen Louise Shaw, Patrick Gerrard Linnane